Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new ...
Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought
The growth investor kicked off this week buying up some high-flying stocks.
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday - Acuity ( NYSE:AYI ) , AES ( NYSE:AES )
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday. Shares of Acuity Inc. ( NYSE:AYI ) rose sharply during Wednesday's session following better-than-expected fourth-quarter earnings. It clocked an adjusted EPS of $5.20, beating the analyst consensus ...
Cathie Wood's China Bet: Ark Buys Alibaba's AI Surge And Baidu's Autonomous Future, Dump's Stock Of Crypto-Pivot Brera - ARK Innovation ETF ( BATS:ARKK )
On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Baidu Inc. ( NASDAQ:BIDU ) , Alibaba Group Holding Ltd. ( NYSE:BABA ) , and Brera Holdings PLC ( NASDAQ:BREA ) . ARK Innovation ETF ( BATS:ARKK ) purchased 52,388 shares of Baidu.
What's Going On With Intellia Therapeutics Stock Thursday - Intellia Therapeutics ( NASDAQ:NTLA )
Intellia Therapeutics Inc. ( NASDAQ: NTLA ) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran ( nex-z ) for the treatment of hereditary ATTR amyloidosis with polyneuropathy ( ATTRv-PN ) .
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran ( nex-z ) in Patients with Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass., Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced longer-term follow-up data from the ongoing Phase 1 study of ...
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran ( nex-z ) in Patients with Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy - Intellia Therapeutics ( NASDAQ:NTLA )
One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three years Stabilization or improvement in disease-related clinical measures observed at 24 months
Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus
Zacks highlights winners like LendingTree, AutoZone, and Johnson & Johnson as its proven stock-picking strategies continue to shine.
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran ( nex-z ) for the Treatment of Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy - Intellia Therapeutics ( NASDAQ:NTLA )
CAMBRIDGE, Mass., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc.
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran ( nex-z ) for the Treatment of Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy
Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight into ATTRv-PN disease-relevant measures Longer-term data to be presented at the 5th International ...
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Strength Seen in Intellia Therapeutics ( NTLA ) : Can Its 29.8% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tesla To Rally More Than 31%? Here Are 10 Top Analyst Forecasts For Friday - Amer Sports ( NYSE:AS ) , Co-Diagnostics ( NASDAQ:CODX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Mizuho raised Sandisk Corporation SNDK price target from $57 to $112.
Intellia Therapeutics Shares Are Ripping Higher: Here's Why - Intellia Therapeutics ( NASDAQ:NTLA )
Intellia completes Phase 3 HAELO trial enrollment within nine months of dosing the first patient. Phase 3 topline data is expected in the first half of 2026. Up Next: Wall Street trader's 35-0 strategy goes public this week. See it first →
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday - Altimmune ( NASDAQ:ALT ) , ASML Holding ( NASDAQ:ASML )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Thursday. Shares of Radian Group Inc. RDN rose sharply during Thursday's session after the company announced it entered into a definitive agreement to acquire Inigo for $1.7 billion.
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran ( lonvo-z ) for Hereditary Angioedema
CAMBRIDGE, Mass., Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it has completed enrollment in the global Phase 3 HAELO study of ...
Cathie Wood's Reshuffle Tuesday: Loads Up On AMD, Figma And Bullish, Trims Tempus AI - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
On Tuesday, Cathie Wood-led Ark Invest executed significant trades, including buying shares of Advanced Micro Devices Inc. AMD and Bullish Inc. BLSH, while selling shares of Tempus AI Inc. TEM. Additionally, Ark purchased Figma Inc. FIG stock, reflecting strategic adjustments in its investment ...
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
These companies are reaching key milestones.
Why Is Xenon Pharmaceuticals ( XENE ) Up 4.2% Since Last Earnings Report?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cathie Wood's Swoops In On Figma's 20% Plunge, Ark Invest Scoops Up Shares Worth $5.9 Million - ARK Next Generation Internet ETF ( BATS:ARKW ) , Figma ( NYSE:FIG )
Ark Invest, led by Cathie Wood, made significant trades on Thursday, notably purchasing shares of Figma Inc. FIG. This move comes as Figma's stock experienced a sharp decline due to disappointing earnings results. Ark Invest acquired 108,238 shares of Figma Inc.
DNA Manufacturing Market to Hit USD 19.56 Billion by 2032 as Demand for Cell and Gene Therapies Continues to Rise
Burlingame, CA, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- The Global DNA Manufacturing Market is estimated to be valued at USD 6.44 Bn in 2025 and is expected to reach USD 19.56 Bn by 2032, exhibiting a compound annual growth rate ( CAGR ) of 17.2% from 2025 to 2032.
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach.
1 Reason Every Investor Should Know About CRISPR Therapeutics ( CRSP )
This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading the developmental race).
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.
Cathie Wood's Raises Wager On Ethereum-Hoarding Bitmine: Ark Buys Stock Of Tom Lee-Backed Company, Dumps Shares Of Sports Betting Giant - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
Ark Invest, led by Cathie Wood, executed significant trades on Wednesday, focusing on Bitmine Immersion Technologies Inc. BMNR and DraftKings Inc. DKNG.
Cathie Wood's Ark Dumps $1.6 Million In Robinhood Stock Amid AI Launch Hype, Dumps Shopify Stock As Well - ARK Fintech Innovation ETF ( BATS:ARKF ) , Robinhood Markets ( NASDAQ:HOOD )
On Thursday, Cathie Wood-led Ark Invest executed significant trades involving Shopify Inc. SHOP and Robinhood Markets Inc. HOOD. Ark Invest, through its Ark Fintech Innovation ETF ARKF, sold 14,914 shares of Robinhood. With the stock closing at $106.30, this transaction was valued at ...
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
Genome Editing Market to Grow at 16.9% CAGR Through 2030
Boston, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, the "Genome Editing: Technologies and Global Markets" is projected to grow from $10.8 billion in 2025 to $23.7 billion by the end of 2030, at a compound annual growth rate ( CAGR ) of 16.9% during the ...
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock - ARK Autonomous Technology & Robotics ETF ( BATS:ARKQ ) , ARK Innovation ETF ( BATS:ARKK )
Ark Invest, led by Cathie Wood, executed notable trades on Monday, focusing on Robinhood Markets Inc. HOOD and Deere & Co. DE. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started Interactive BrokersTrade global markets with low costs and pro-level tools at ...
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday - Aflac ( NYSE:AFL ) , American Public Education ( NASDAQ:APEI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stephens & Co. cut Atlassian Corporation TEAM price target from $221 to $202.
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia ( NTLA ) Q2 Revenue Jumps 106%
Intellia Therapeutics ( NASDAQ:NTLA ) , a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a significant increase in collaboration revenue to $14.2 million ( GAAP ) for Q2 2025, which beat the ...
Intellia Therapeutics, Inc. ( NTLA ) Reports Q2 Loss, Beats Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded an inducement grant to five new ...
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Intellia Therapeutics ( NASDAQ:NTLA )
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Intellia ( NTLA ) To Contact Him Directly To Discuss Their Options
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates - Intellia Therapeutics ( NASDAQ:NTLA )
CAMBRIDGE, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. NTLA, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference ...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
CAMBRIDGE, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in ...
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks.
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
Why Is KalVista Pharmaceuticals Stock Soaring On Monday? - KalVista Pharma ( NASDAQ:KALV )
Ekterly approved by FDA as the first oral on-demand treatment for HAE in patients 12 and older. KONFIDENT-S trial showed a median 10-minute treatment time after HAE attack onset. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news fast. Now 60% off this 4th of July.
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Eli Lilly ( NYSE:LLY ) , Verve Therapeutics ( NASDAQ:VERV )
Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Last Chance: See the "Power Pattern" That Delivered Winners 9 Out of the Last 10 Summers. Get The Details Here
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine ( NASDAQ: EDIT ) is a promising clinical-stage company that has captured Wall Street's attention at the ...
